Biogen Inc. $BIIB Position Boosted by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 2,248.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 113,189 shares of the biotechnology company’s stock after acquiring an additional 108,370 shares during the period. E. Ohman J or Asset Management AB’s holdings in Biogen were worth $25,567,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. boosted its holdings in shares of Biogen by 3,284.1% in the 3rd quarter. SBI Securities Co. Ltd. now owns 49,780 shares of the biotechnology company’s stock worth $11,244,000 after buying an additional 48,309 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Biogen by 7,950.0% in the third quarter. Pinnacle Bancorp Inc. now owns 1,288 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 1,272 shares during the period. Massachusetts Wealth Management raised its holdings in shares of Biogen by 7.0% in the 3rd quarter. Massachusetts Wealth Management now owns 3,455 shares of the biotechnology company’s stock valued at $780,000 after acquiring an additional 225 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Biogen by 1,162.1% in the third quarter. Crossmark Global Holdings Inc. now owns 125,959 shares of the biotechnology company’s stock valued at $28,452,000 after purchasing an additional 115,979 shares in the last quarter. Finally, Albion Financial Group UT lifted its holdings in shares of Biogen by 2,833.3% during the 3rd quarter. Albion Financial Group UT now owns 176 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 170 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

BIIB stock opened at $253.84 on Friday. The stock’s fifty day moving average price is $222.78 and its 200-day moving average price is $205.73. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The company has a market cap of $37.50 billion, a P/E ratio of 44.93, a price-to-earnings-growth ratio of 2.68 and a beta of 0.09. Biogen Inc. has a 1 year low of $138.00 and a 1 year high of $254.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the firm earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts forecast that Biogen Inc. will post 12.31 earnings per share for the current year.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo raised its price target on Biogen, adding to a series of upward analyst revisions and reinforcing optimism about the company’s outlook. Biogen Stock Gets Price Target Boost from Wells Fargo
• Positive Sentiment: Bank of America increased its Biogen price target to $244 from $219. Although the firm maintained a Neutral rating, the revision reflects improved expectations as analysts update their models ahead of earnings. Biogen on BofA Price Target Hike
• Positive Sentiment: Several previews suggest Biogen could exceed third-quarter earnings estimates, supported by favorable analyst expectations and the potential for continued progress across its late-stage drug pipeline. Biogen Expected to Beat Earnings Estimates
• Neutral Sentiment: Wedbush kept a Hold rating on Biogen, indicating that valuation and near-term catalysts may already be reflected in the share price. Wedbush Remains a Hold on Biogen
• Negative Sentiment: Bank of America’s $244 target remains below the stock’s recent trading level, implying limited upside or potential downside despite the target increase. Analysts also characterize the upcoming quarter as relatively quiet, and earnings previews warn that disappointment remains possible.

Analyst Ratings Changes

Several analysts have issued reports on BIIB shares. Wells Fargo & Company upped their target price on Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday. Stifel Nicolaus set a $242.00 price target on shares of Biogen in a report on Thursday, September 10th. Guggenheim increased their target price on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Canaccord Genuity Group lifted their price objective on Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Needham & Company LLC upped their price objective on shares of Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and a consensus target price of $241.89.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.